Dr. Arvind Neelakantan, MD

Dr. Neelakantan practices at Glaucoma Center of Texas in Rockwall, Texas.

Dr. Neelakantan's NPI, 1205889052, was assigned on May 19, 2006. Dr. Neelakantan graduated from Topiwala National Medical College in 1989. Dr. Neelakantan holds Texas license M5851.

Dr. Neelakantan's primary practice is Glaucoma Center of Texas, at 2380 S Goliad St, Rockwall, TX 75032 in Rockwall County. The practice phone is (214) 739-3900.

Dr. Neelakantan's primary practice is Glaucoma Center of Texas in Rockwall, Texas. The medical group on file is University of Texas Southwestern Medical Center. Dmand AI also links Dr. Neelakantan to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Neelakantan practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Neelakantan's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Neelakantan is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Neelakantan's licenses on file in 2 states: Texas and Florida.

Dmand AI lists cataract, cataract surgery with lens implant, cold sores or genital herpes, dry eye, eyelid inflammation, glaucoma, glaucoma surgery and secondary membranaous cataract surgery among the conditions Dr. Neelakantan treats.

CMS data shows 3,297 Medicare services from Dr. Neelakantan across 16 procedure codes in 2024, for 604 Medicare patients. Medicare paid $189,996 for them.

CMS counts 604 Medicare patients who saw Dr. Neelakantan in 2024. The largest group is 75 to 84, with 249 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.18, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Neelakantan's median patient age at 72, with 52% women.

In 2024, Dr. Neelakantan wrote 5,880 Medicare Part D claims for 1,139 patients. 64% of them were for generic drugs. CMS names the drug for 5,784 of them, across 28 drugs with 11 or more claims each, at $425,367 in total drug cost. In 2023, CMS named 5,367 claims across 29 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Neelakantan for performance year 2024, reported individually. Dr. Neelakantan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 111 procedures of cataract surgery by Dr. Neelakantan, more than 76% of the clinicians it reports for that procedure.

Dmand AI links 13 papers to Dr. Neelakantan, published from 2011 to 2014. The most frequent topics are Glaucoma, Intraocular Pressure and Conjunctiva. Dr. Neelakantan has published most often in Indian J Ophthalmol. Dr. Neelakantan's most frequent co-authors are David Gray Godfrey, MD, Donald Lyle Budenz, MD and Robert T. Chang, MD.

Dmand AI links Dr. Neelakantan to 1 clinical trial. Conditions studied include Glaucoma and Ocular Hypertension.

CMS Open Payments shows 432 general payments to Dr. Neelakantan from 25 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 56% of the total. Aerie Pharmaceuticals, Inc. paid the most, $58,191.

Dmand AI lists 2 awards for Dr. Neelakantan, most recently CMS Stage 1 EHR in 2013.

Dr. Neelakantan graduated from Topiwala National Medical College in 1989. Dr. Neelakantan is a member of AAO.

Dr. Neelakantan is in network with 22 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. PPO plans come from the most carriers, 14. Check the plan with the practice before a visit.